Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Total Current Liabilities (2016 - 2025)

Fortress Biotech (FBIO) has 13 years of Total Current Liabilities data on record, last reported at $54.1 million in Q3 2025.

  • For Q3 2025, Total Current Liabilities fell 23.1% year-over-year to $54.1 million; the TTM value through Sep 2025 reached $54.1 million, down 23.1%, while the annual FY2024 figure was $71.4 million, 15.91% down from the prior year.
  • Total Current Liabilities reached $54.1 million in Q3 2025 per FBIO's latest filing, down from $57.5 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $129.5 million in Q1 2023 and bottomed at $53.8 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $89.5 million, with a median of $87.7 million recorded in 2024.
  • Peak YoY movement for Total Current Liabilities: skyrocketed 176.85% in 2021, then crashed 41.25% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $101.0 million in 2021, then grew by 26.4% to $127.7 million in 2022, then crashed by 33.52% to $84.9 million in 2023, then dropped by 15.91% to $71.4 million in 2024, then decreased by 24.27% to $54.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $54.1 million in Q3 2025, $57.5 million in Q2 2025, and $73.7 million in Q1 2025.